A review of the use of modafinil for attention-deficit hyperactivity disorder

Expert Review of Neurotherapeutics
Danielle C Turner

Abstract

Modafinil (Provigil) is a novel wakefulness-promoting agent that has been shown to have greater efficacy than placebo in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. In particular, three large, drug-company sponsored trials of a film-coated formulation of modafinil (modafinil-ADHD; Sparlon) in children and adolescents with ADHD demonstrated consistent improvements in ADHD symptoms compared with placebo. Mean reductions in symptom ratings (measured using the ADHD-Rating Scale-IV school version questionnaire) ranged from 15.0 to 19.7 (7.3 to 10.1 for placebo). The most common adverse events were insomnia, headache and decreased appetite. Modafinil was generally well tolerated with most side effects considered mild to moderate in severity. Modafinil may have advantages over current therapies for ADHD in that it can be administered once daily and has fewer reinforcing properties than traditional stimulants. Modafinil could potentially be a valuable new treatment option for patients with ADHD. However, rigorous comparative studies with current first-line treatments for ADHD and longer-term independent studies are necessary before modafinil's role in the treatment of ADHD can be fully estab...Continue Reading

References

Mar 1, 1996·Journal of the American Academy of Child and Adolescent Psychiatry·J BiedermanT Spencer
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·J S LinM Jouvet
Aug 6, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·J BiedermanB Zallen
Jan 29, 2000·Journal of Clinical and Experimental Neuropsychology·A J WalkerP S Sachdev
Jul 29, 2000·Biological Psychiatry·S V FaraoneA E Doyle
Feb 24, 2001·Journal of Child and Adolescent Psychopharmacology·F B Taylor, J Russo
Feb 24, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·T A Rugino, T C Copley
Mar 7, 2002·Archives of Pediatrics & Adolescent Medicine·William J BarbaresiSteven J Jacobsen
Mar 7, 2002·Archives of General Psychiatry·Rajesh NarendranCynthia A Pristach
Apr 23, 2002·Journal of Attention Disorders·Patricia Murphy
May 25, 2002·Journal of Child Neurology·Daniel L Hurst, Walter Lajara-Nanson
Jul 30, 2002·The Journal of Clinical Psychiatry·Stephen M Stahl
Nov 6, 2002·Psychopharmacology·Danielle C TurnerBarbara J Sahakian
Jan 23, 2003·Clinical Pharmacokinetics·Philmore Robertson, Edward T Hellriegel
Jan 30, 2003·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Michael T Willoughby
Feb 20, 2003·The Journal of Clinical Psychiatry·Andrew A NierenbergMaurizio Fava
Mar 5, 2003·Neuroscience Letters·Tomoko IshizukaAtsushi Yamatodani
Mar 7, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Charles H AdlerJudy Tiede
Apr 29, 2003·The Journal of Clinical Psychiatry·Eugene H MakelaWilliam D Cutlip
Jun 5, 2003·The American Journal of Psychiatry·Monique ErnstKaren Bolla
Jun 12, 2003·Neuromuscular Disorders : NMD·K TalbotD Hilton-Jones
Oct 29, 2003·Pediatric Neurology·Thomas A Rugino, Teresa C Samsock
Nov 5, 2003·The American Journal of Psychiatry·Nora D Volkow, James M Swanson
Jan 8, 2004·Journal of Clinical Psychopharmacology·Stephen V FaraoneJoseph Biederman
Jan 8, 2004·Journal of Clinical Psychopharmacology·Charles DeBattistaJennifer Poirier
Feb 26, 2004·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Mitul A MehtaBarbara J Sahakian
Mar 10, 2004·Pharmacology, Biochemistry, and Behavior·Delia C RandallSandra E File
Mar 25, 2004·Biological Psychiatry·Joseph BiedermanElizabeth Cadogen
Apr 16, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Danielle C TurnerBarbara J Sahakian
May 4, 2004·Biological Psychiatry·Danielle C TurnerBarbara J Sahakian
Jun 29, 2004·Psychopharmacology·Ulrich MüllerPeter Bublak
Aug 27, 2004·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Hugh MyrickSteven LaRowe
Sep 1, 2004·Psychopharmacology·Danielle C TurnerBarbara J Sahakian
Oct 20, 2004·The Journal of Clinical Psychiatry·Timothy E Wilens, William Dodson
Nov 5, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Charles A DackisCharles P O'Brien

❮ Previous
Next ❯

Citations

Aug 30, 2008·Neuropsychiatric Disease and Treatment·Dusan KolarLily Hechtman
Oct 18, 2007·Expert Review of Neurotherapeutics·Lucy CumynLily Hechtman
Oct 29, 2008·Bioorganic & Medicinal Chemistry·Carmela De RisiAugusto C Veronese
Sep 4, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shahrokh AmiriShahin Akhondzadeh
Jun 6, 2009·Journal of Psychopharmacology·S E Winder-RhodesU Müller
Sep 27, 2015·Pharmacological Reviews·Christopher L GermanAnnette E Fleckenstein
Apr 17, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Szilvia VasA Jennifer Morton
Apr 5, 2017·Psychopharmacology·Yumiko IkedaHidenori Suzuki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.